← Back to patent-cliff list
64CU-DOTA-ECL1i
Tier C — Watch / trade64CU-DOTA-ECL1i
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：CCL2
Indications (approved)：Head and neck squamous cell carcinoma, 动脉硬化, 颈动脉疾病, Heart disease
Regional status
US
Phase II
2026-08-31
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 64CU-DOTA-ECL1i?
Approved indications include: Head and neck squamous cell carcinoma, 动脉硬化, 颈动脉疾病, Heart disease.
When does the 64CU-DOTA-ECL1i patent expire?
No public expiry year is available for 64CU-DOTA-ECL1i yet; this page updates once verified.
How do I get a quote for 64CU-DOTA-ECL1i intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29